头颈鳞状细胞癌免疫治疗的研究进展

打开文本图片集

关键词：头颈鳞状细胞癌；免疫检查点抑制剂；围手术期治疗；诱导治疗 中图分类号：R739.6；R739.8文献标识码：A 文章编号：1000-503X（2025）05-0850-13 DOI： 10.3881/j.issn.1000-503X.16477

ABSTRACT： Head and neck squamous cell carcinoma （HNSCC） associated with a poor prognosis and diminished qualityoflife for patients is the most prevalent pathological type among head and neck tumors.Currently，the standard treatment modalities comprise systemic therapies （including chemotherapy，targeted therapy， and immunotherapy）and local therapies（surgeryand radiotherapy）.Immunotherapy，characterized by high specificity and low toxicity，is progressively expanding fromadvanced pallative care to the stage of locallyadvanced curative treatment and has demonstrated promising eficacy.This review summarizes the latest advances in immunotherapy for HNSCC，aiming to provide reference for optimizing clinical management strategies and facilitating the clinical research.

Key words：headand neck squamous cellcarcinoma；immune checkpoint inhibitor；perioperative therapy；induction therapy ActaAcadMedSin，2025，47（5） ：850-862

头颈部肿瘤位列全球第六常见癌症， 90% 以上组织学表现为鳞状细胞癌，主要解剖部位包括口腔、口咽、下咽和喉部，2022年我国新发病例7.9万人，死亡病例4.9万人[1-2]。（剩余31204字）